
    
      To assess the clinical efficacy of allogeneic umbilical cord mesenchymal stem cell
      transplantation in the treatment of patients with severe type 1 diabetes, defined as with the
      history of diabetic ketoacidosis from diagnosis. All the patients are intravenously
      administrated with single-dose or double-dose umbilical cord mesenchymal stem cell and
      followed up for 36 months. Clinical and laboratory manifestations are compared before and
      after transplantation.
    
  